Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

William Demant Holding A/S: Annual Report 2017


Posted on: 22 Feb 18

Company announcement no 2018-02                               22 February 2018
Publication of Annual Report 2017

Organic growth of 9% in Group revenue, with strong performances by all business activities
Hearing aid wholesale generated organic growth of 11% and gained market share
Adjusted EBIT of DKK 2,504 million and growth of 25% in underlying EBIT

This announcement includes the highlights from the Annual Report 2017: 
  

  • Consolidated revenue for 2017 totalled DKK 13,189 million, matching a strong growth rate of 10% of which organic and acquisitive growth accounted for 9 and 2 percentage points, respectively, and exchange rates accounted for -1 percentage point.
  • Due to innovation and strong commercial execution, all three business activities gained market share in 2017, resulting in organic growth rates of 8% in Hearing Devices, 28% in Hearing Implants and 11% in Diagnostic Instruments. Our hearing aid wholesale business delivered strong organic growth of 11% due to a combination of positive trends in geography, channel and product mixes, continuously strong performance by Oticon Opn throughout the year and new products launched by Bernafon and Sonic in the second half-year. Our retail business delivered an organic growth rate of 4%.
  • Operating profit (EBIT) increased by 18% to DKK 2,504 million before restructuring costs of DKK 166 million, which was within our guidance of DKK 2,300-2,600 million and despite a negative exchange rate impact of DKK 103 million compared to 2016. The corresponding EBIT margin increased by 1.3 percentage points from 17.7% to 19.0%, and the underlying EBIT was up by 25%, corresponding to a margin increase of 2.3 percentage points. The significant improvement in EBIT was mainly driven by strong revenue growth, mix changes and cost savings from strategic initiatives. The reported EBIT for 2017 was DKK 2,338 million, and earnings per share increased by 24% to DKK 6.84.
  • Cash flow from operating activities (CFFO) increased by 15% to DKK 2,023 million before restructuring costs (reported CFFO of DKK 1,872 million). Free cash flow before acquisitions amounted to DKK 1,387 million, up by 13% on 2016.
  • In 2018, we are guiding for an operating profit (EBIT) of DKK 2,550-2,850 million before restructuring costs of DKK 150 million, and we expect to buy back shares worth DKK 1.5-2.0 billion.


Comments by the President & CEO

"The past year's impressive performance once again confirms that we deliver on our broad hearing healthcare strategy and our vision to make a positive change for people suffering from hearing loss. We have in 2017 reached more people than ever and succeeded in delivering strong growth, and all our business activities have gained market share. In William Demant, we're committed to supporting our customers and - through our focus on innovation - providing solutions, such as the outstanding Oticon Opn hearing aid, that help people with hearing loss connect with the world around them. As a result of this focus and a lot of hard work, 2017 was a record year with a very satisfactory increase in earnings for William Demant, and I'm confident that we can continue the strong momentum into 2018," says Søren Nielsen, President & CEO of William Demant Holding A/S.   

Niels B. Christiansen                                                          Søren Nielsen
Chairman of the Board                                                       President & CEO

The full Annual Report 2017 for William Demant Holding A/S totalling 130 pages is attached to this announcement.

*******

Further information:
Søren Nielsen, President & CEO
Phone +45 3917 7300
www.demant.com
Other contacts:
René Schneider, CFO
Søren B. Andersson, VP IR
Søren Holm Printz, IR
Trine Kromann-Mikkelsen, Media Relations




 
2017  

2016
2015 2014 2013 Development
2016-2017
Key figures, DKK million            
Revenue 13,189 12,002 10,665 9,346 8,959 10%
Gross profit 10,026 9,030 7,895 6,813 6,518 11%
Gross profit - adjusted* 10,064 9,102 7,895 - - 11%
R&D costs 919 839 763 680 634 10%
EBITDA 2,742 2,346 2,203 2,055 2,028 17%
Amortisation and depreciation etc. 404 404 325 294 292 0%
Operating profit (EBIT) 2,338 1,942 1,878 1,761 1,736 20%
Operating profit (EBIT) - adjusted* 2,504 2,130 1,902 - - 18%
Net financial items -111 -101 -69 -70 -72 10%
Profit before tax 2,227 1,841 1,809 1,691 1,664 21%
Profit for the year 1,759 1,464 1,439 1,327 1,286 20%
Financial ratios            
Gross profit margin 76.0% 75.2% 74.0% 72.9% 72.8% -
Gross profit margin - adjusted* 76.3% 75.8% 74.0% - - -
EBITDA margin 20.8% 19.5% 20.7% 22.0% 22.6% -
Profit margin (EBIT margin) 17.7% 16.2% 17.6% 18.8% 19.4% -
Profit margin (EBIT margin) - adjusted* 19.0% 17.7% 17.8% - - -
Earnings per share (EPS), DKK 6.8 5.5 5.3 4.8 4.5 24%
Return on equity 24.0% 21.5% 23.7% 24.7% 28.0% -

Earnings per share (EPS) is per share of nominally DKK 0.20.
* Adjusted for one-off costs related to restructuring activities.

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/f7da49e5-d8d5-4a1c-8503-34875ae42586

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/70eaacda-7838-4ecf-bc1a-30ecb443b79b

GlobeNewswire
globenewswire.com

Last updated on: 22/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.